PCSK9: Patients with high Lipoprotein (a) could benefit more

被引：0
|
作者：
Franke, Katharina
机构：
来源：
AKTUELLE KARDIOLOGIE | 2019年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PCSK9 Inhibition could be Effective for Acute Myocardial Infarction
    Gencer, Baris
    Mach, Francois
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (06) : 1016 - 1026
  • [32] Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
    Afanasieva, Olga
    Ezhov, Marat, V
    Klesareva, Elena
    Razova, Oksana
    Chubykina, Uliana
    Egiazaryan, Mane
    Sherstyuk, Ekaterina
    Afanasieva, Marina
    Utkina, Elena
    Pokrovsky, Sergei
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2020, 7 (04) : 1 - 11
  • [33] Just Price for PCSK9 Inhibitors: No less, No More
    Nasir, Khurram
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (21):
  • [34] THE USE OF PCSK9 INHIBITORS COULD REDUCE PROTEINURIA IN CHRONIC KIDNEY DISEASE PATIENTS
    Munoz Ramos, Patricia
    Gil Giraldo, Leydy Yohana
    Reque, Javier
    Quiroga, Borja
    Chiva, Vicente Alvarez
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 485 - 485
  • [35] EFFECTS OF LIPOPROTEIN APHERESIS (LA) ON SERUM PCSK9 LEVELS
    Julius, U.
    Rader, D.
    Gordon, B.
    Moriarty, P.
    Polk, D.
    Parhofer, K. G.
    ATHEROSCLEROSIS, 2014, 235 (02) : E59 - E60
  • [36] Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) Levels
    Sbrana, Francesco
    Bigazzi, Federico
    Dal Pino, Beatrice
    Toma, Maddalena
    Ripoli, Andrea
    Sampietro, Tiziana
    THERAPEUTIC APHERESIS AND DIALYSIS, 2019, 23 (04) : 385 - 386
  • [37] Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors
    Safarova, Maya S.
    Kullo, Iftikhar J.
    ATHEROSCLEROSIS, 2022, 361 : 30 - 31
  • [38] PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions
    Hilvo, Mika
    Simolin, Helena
    Metso, Jari
    Ruuth, Maija
    Oorni, Katariina
    Jauhiainen, Matti
    Laaksonen, Reijo
    Baruch, Amos
    ATHEROSCLEROSIS, 2018, 269 : 159 - 165
  • [39] The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
    Chan, Dick C.
    Watts, Gerald F.
    CLINICAL THERAPEUTICS, 2023, 45 (11) : 1034 - 1046
  • [40] EFFECT OF COMBINATION THERAPY WITH PCSK9 INHIBITORS AND LIPOPROTEIN APHERESIS
    Pottle, A.
    Browne, C.
    Neves, E.
    Barbir, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 34 : E9 - E9
12345